89 percent and theaverage jumbo 30year fixed rate jumped to 7

The Companyhas tried, whenever possible, to identify these forward-looking statementsusing words such as"expects," "anticipates," "believes," "targets," "goals,""projects," "intends," "plans," "seeks," "estimates," "may," "will," "should"and similar expressions. Similarly, statements in this press release thatdescribe the Company's business strategy, outlook, objectives, plans,intentions or goals are also forward-looking statements. Accordingly, suchforward-looking statements involve known and unknown risks, uncertainties andother factors that could cause the Company's actual results, performance orachievements and levels of future dividends to differ materially from thoseexpressed in, or implied by, these statements. These risks and uncertaintiesmay include, but are not limited to: actual or perceived weakness in the U.S.and global economy and fluctuations in consumer spending and disposableincome, uncertainty regarding U.S. and global economic conditions, theCompany's ability to successfully introduce and sell new products, theCompany's ability to successfully integrate the operations of newly acquiredand/or licensed brands without disruption to its other business activities,changes in consumer demand for the Company's products, risks relating to thefashion and retail industry, import restrictions, competition, seasonality,commodity price and exchange rate fluctuations, changes in local or globaleconomic conditions, and the other factors discussed in the Company's AnnualReport on Form 10-K and other filings with the Securities and ExchangeCommission. These statements reflect the Company's current beliefs and arebased upon information currently available to it. Be advised that developmentssubsequent to this press release are likely to cause these statements tobecome outdated with the passage of time.SOURCEMovado Group, Inc.Investor Relations, Suzanne Rosenberg, Vice President, CorporateCommunications, 1-201-267-8000; or Financial Dynamics, Leigh Parrish orStephanie Rich, 1-212-850-5600.

Complements the RBM Rat Kidney Panel developed in conjunction with theCritical Path InitiativeAUSTIN, Texas, Jan 15 /PRNewswire/ Rules-Based Medicine, Inc. The Human Kidney MAP will be used in clinicaltrials to reveal early signs and locations of drug-induced kidney damage,known as renal toxicity or nephrotoxicity, thereby guiding important decisionson lead compounds and dosage."The Human Kidney MAP is an important response to the FDA's Critical PathInitiative, which highlighted the need for new tools to better understand thesafety profile of new drugs," said Craig Benson, RBM president and chiefexecutive officer. "By providing a quantitative and predictive multiplexedbiomarker test for renal toxicity, we will help our customers improve safety,mitigate risk, and reduce costs associated with drug development."RBM's Human Kidney MAP utilizes a multiplexed panel of 16 biomarkers to detectearly renal damage and pinpoint the location within the kidney. Both the U.S.Food and Drug Administration (FDA) and the European Medicines Agency (EMEA)recently decided to accept data related to certain biomarkers of kidney damageas part of the drug approval process in conjunction with new safetyinitiatives. Historically, regulatory agencies have required drug companies toprovide results of blood urea nitrogen (BUN) and serum creatinine tests asindicators of kidney damage. Studies, however, suggest these tests detect onlylate signs of kidney damage and provide no information on the location ofdamage.The Human Kidney MAP was developed using a translational medicine approach.

The Human Kidney MAP contains many of the same biomarkers and isdesigned to detect general signs of kidney damage. Drugs in circulation areconcentrated up to 1000-fold in the kidney compared to plasma, magnifying thepotential for renal toxicity of any drug.Kidney damage also occurs in connection with diseases such as diabetes,hypertension, and autoimmune conditions, among others. RBM has established andis seeking additional collaborations with leading academic and pharmaceuticalresearchers to develop diagnostic applications based on the Human Kidney MAP.About Rules-Based MedicineRules-Based Medicine (RBM) provides comprehensive protein biomarker productsand services centered on its Multi-Analyte Profiling (MAP) technology. The Company also offers innovative and proprietary exvivo testing systems such as TruCulture(TM), the first fully-closed,reproducible whole blood culture system. RBM is actively developingmultiplexed diagnostic tests to detect the presence of complex diseases andconditions in areas of unmet medical need such as neuropsychiatry, nephrology,immunology and cardiology More information about RBM is located at RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-Based MedicineInc.SOURCERules-Based Medicine, Inc.Company Contact, Sam LaBrie, Ph.D., Vice President, Corporate Development ofRules-Based Medicine, Inc., 1-512-835-8026, ext. 287,; or Additional Media Contact, Nadine Padilla,LLC, 1-619-507-9306, , for Rules-Based Medicine, Inc..

15, /PRNewswire-FirstCall/ Mortgage rates fell for the thirdweek in a row, tying a record low last seen in 2003. According toBankrate 's weekly national survey, the average 30-year fixed mortgage ratedropped to 5.28 percent with an average of 0.42 discount and originationpoints. (Logo: http:// )The average 15-year fixed rate mortgage inched higher to 4.89 percent and theaverage jumbo 30-year fixed rate jumped to 7.07 percent. Adjustable ratemortgages were lower, with the average 5/1 ARM retreating to 5.51 percent. Mortgage rates continued their decline amid dour economic reports and theFederal Reserve's ongoing program of mortgage bond purchases. Similarly, today's low rates have produced a flurry ofrefinancing activity and the likelihood of rates remaining low at leastthrough the first half of the year is promising for potential home buyers aswell. Lower mortgage rates have opened the door to refinancing for homeowners withequity.